Acetylcholine Receptor Pathway and Lung Cancer

Slides:

Advertisements

Similar presentations

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages

Advertisements

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung Sai-Hong.

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer Timothy R. Wassenaar, MD, Jens C.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Axl Receptor Axis: A New Therapeutic Target in Lung Cancer

OPG/RANKL/RANK Pathway as a Therapeutic Target in Cancer

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Overexpression of Muscarinic Receptor 3 Promotes Metastasis and Predicts Poor Prognosis in Non–Small-Cell Lung Cancer Gengpeng Lin, MD, Longhua Sun,

EGFR T790M Mutation: A Double Role in Lung Cancer Cell Survival?

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Inflammation, Epithelial to Mesenchymal Transition, and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance Kostyantyn Krysan, PhD,

Electronic Updates for JTO Readers

Hedgehog Signaling Pathway and Lung Cancer

Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.

Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Lung Cancer: A Systematic Review with Meta-Analysis Ping Zhan, MD,

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer Timothy R. Wassenaar, MD, Jens C.

Frank Detterbeck, MD Journal of Thoracic Oncology

Prognostic Impact of Fibroblast Growth Factor 2 in Non-small Cell Lung Cancer: Coexpression with VEGFR-3 and PDGF-B Predicts Poor Survival Tom Donnem,

Vascular Endothelial Growth Factor (VEGF) Pathway

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Influence of Apoptosis and Cell Cycle Regulator Proteins on Chemotherapy Response and Survival in Stage IIIA/IIIB NSCLC Patients José L. Morero, MD,

The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials Krista.

LKB1 Regulated Pathways in Lung Cancer Invasion and Metastasis

Immune modulation by neuronal electric shock waves

Serum Vascular Endothelial Growth Factor and COX-2/5-LOX Inhibition in Advanced Non-small Cell Lung Cancer: Cancer and Leukemia Group B Martin.

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition Sai-Hong.

Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non–Small Cell Lung Cancer Patient Jordi Remon, MD, Anas Gazzah, MD, Benjamin Besse,

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Yang Zhang, MD, Haiquan Chen, MD, PhD

Chemotherapy in Patients ≥80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6 Paul J. Hesketh, MD, Rogerio C. Lilenbaum,

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Non–Small-Cell Lung Cancer with HER2 Exon 20 Mutation: Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment Gerald S. Falchook, MD,

SRC and STAT Pathways Journal of Thoracic Oncology

Yan Feng, MD, Praveena S. Thiagarajan, PhD, Patrick C. Ma, MD

Mitotic Inhibitors Journal of Thoracic Oncology

A Translational View of the Molecular Pathogenesis of Lung Cancer

Mirror Mirror on the Wall, Who Is the Fairest of Them All

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Relationship between Response and Survival in More Than 50,000 Patients with Advanced Non-small Cell Lung Cancer Treated with Systemic Chemotherapy in.

Benjamin Solomon, MBBS, PhD, Richard B. Pearson, PhD

Predictors of Surgery and Consult with an Oncologist for Adjuvant Chemotherapy in Early Stage NSCLC Patients in Alberta, Canada Marcy Winget, PhD, Jennifer.

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Adjuvant Chemotherapy for Non-small Cell Lung Cancer: Practice Patterns and Outcomes in the General Population of Ontario, Canada Christopher M. Booth,

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

The Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Lung Cancer: Still Following the Right TRAIL? Emmet E. McGrath, MB, PhD Journal of Thoracic.

Genetic Changes in Squamous Cell Lung Cancer: A Review

Roger Hakimian, MD, Hongbin Fang, PhD, Leno Thomas, MD, Martin J

European Lung Cancer Conference (ELCC) 2016 Organisation

Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non–Small-Cell Lung Cancer Charles M.

The new kid on the block(ade) of the IGF-1 receptor

Overexpression of Muscarinic Receptor 3 Promotes Metastasis and Predicts Poor Prognosis in Non–Small-Cell Lung Cancer Gengpeng Lin, MD, Longhua Sun,

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Liseth L. van den Berg, MD, Theo J. Klinkenberg, MD, Harry J. M

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

A Review of First-Line Treatment for Small-cell Lung Cancer

Mark A. Socinski, MD Journal of Thoracic Oncology

Role of the Wnt Signaling Pathway and Lung Cancer

Robert Comis, MD, The Passing of a “Lung Man”

Presentation transcript:

Acetylcholine Receptor Pathway and Lung Cancer Frederik B. Thunnissen, MD, PhD Journal of Thoracic Oncology Volume 4, Issue 8, Pages 943-946 (August 2009) DOI: 10.1097/JTO.0b013e3181ad83fc Copyright © 2009 Terms and Conditions

FIGURE 1 The acetyholine receptor (AchR) pathway plays a pivotal role in promotion of lung cancer. Nicotine binds with higher affinity than physiologic ligand acetylcholine (Ach) to nicotinic AchR (nAchR). Binding of ligand to nAchR results in Ca++ influx, binding of ²-arrestin and SRC. One subsequent effect is increase of Ach synthesis. Ach binds to nAchR and to muscarinic AchR (mAchR). The coexpression of Ach and AchR has been shown in SCLC and NSCLC, pointing to an autocrine or paracrine loop. Lynx1 modulates the effect of activated nAchR. nAchRs may show less desensitization from endogenous Ach and exogenous nicotine in case of decreased levels of Lynx1. Ligand binding to nAchR and mAchR lead to activated MAPK and proliferation after a few hours. Nicotine leads to increase fibronectin synthesis, which binds extracellular to ±5²1 integrin. This in turn results in increase of MAPK, leading to proliferation with a peak after 5 days. Nicotine inhibits mitochondrial apoptosis induced by chemotherapy, UV radiation, and hydrogenperoxide, thereby, prolonging cell survival. Nicotine decreases E-cadherin and ²-catenin and in combination with fibronectin it increases proinvasive effects possibly due to the loss of contact inhibition. Nicotine also leads to increase in HIF1±, with subsequent increase of VEGF stimulating neoangiogenesis. All these effects can be blocked at the level of the nAchR and the mAchR. Journal of Thoracic Oncology 2009 4, 943-946DOI: (10.1097/JTO.0b013e3181ad83fc) Copyright © 2009 Terms and Conditions